Lantheus (NASDAQ:LNTH – Get Free Report) posted its quarterly earnings results on Thursday. The medical equipment provider reported $1.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.45, FiscalAI reports. Lantheus had a net margin of 17.28% and a return on equity of 29.26%. The business had revenue of $389.91 million during the quarter, compared to analysts’ expectations of $355.74 million. During the same quarter last year, the company posted $1.27 earnings per share. The business’s quarterly revenue was up 1.5% on a year-over-year basis.
Lantheus Price Performance
Shares of NASDAQ:LNTH traded down $0.09 during trading on Friday, reaching $100.61. 1,575,979 shares of the company’s stock traded hands, compared to its average volume of 1,090,931. The company has a quick ratio of 2.89, a current ratio of 3.25 and a debt-to-equity ratio of 0.42. Lantheus has a fifty-two week low of $50.15 and a fifty-two week high of $111.86. The company has a 50-day simple moving average of $100.27 and a 200-day simple moving average of $92.06. The firm has a market cap of $6.57 billion, a PE ratio of 24.78 and a beta of 0.01.
Wall Street Analysts Forecast Growth
LNTH has been the topic of a number of research analyst reports. TD Cowen lowered shares of Lantheus from a “buy” rating to a “hold” rating and dropped their price objective for the company from $110.00 to $102.50 in a report on Monday, August 3rd. Leerink Partners set a $102.50 target price on Lantheus in a research note on Monday, August 3rd. B. Riley Financial cut Lantheus from a “buy” rating to a “hold” rating in a research report on Monday, August 17th. William Blair set a $102.50 price target on Lantheus in a research report on Monday, August 3rd. Finally, Truist Financial downgraded Lantheus from a “buy” rating to a “hold” rating and dropped their price target for the company from $125.00 to $102.50 in a research note on Monday, August 3rd. Three equities research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. According to data from MarketBeat, Lantheus currently has a consensus rating of “Hold” and a consensus target price of $107.44.
Read Our Latest Research Report on Lantheus
About Lantheus
Lantheus Holdings, Inc is a diagnostic imaging and radiopharmaceutical company that develops, manufactures and commercializes products used to help physicians detect, characterize and monitor disease. Its portfolio supports imaging in areas including oncology, cardiology and other medical specialties.
The company’s products include DEFINITY, an ultrasound-enhancing agent used in cardiac and other ultrasound examinations, and PYLARIFY, a prostate-specific membrane antigen (PSMA) PET imaging agent used to help identify and manage prostate cancer.
Read More
- Five stocks we like better than Lantheus
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.
